Semma Therapeutics: Harvard and Semma Therapeutics improve insulin yield from stem cells
The findings, published in Nature, may be used to improve beta cell transplants for patients with type 1 diabetes
Read full article »
Semma Therapeutics is a biotechnology company that develops and commercializes stem cell-based therapies for the treatment of diabetes.
Read more